IDWeek 2014: HIV

IDWeek 2014: HIV

EVG/COB/FTC/TDF Single Tab Improves Fasting Triglycerides in HIV Patients

Switching to single-tablet co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir (EVG/COB/FTC/TDF) from a multi-tablet ritonavir-boosted protease inhibitor (PI + RTV) with emtricitabine and tenofovir DF (FTC/TDF) regimen significantly increased rates of virologic suppression and declined fasting triglycerides in patients with HIV-1 infection.